Injuries to the spinal cord partially or completely disrupt the neural pathways between the brain and the limbs. The consequences for the representation of the affected limbs in the brain can be drastic. Researchers have now measured how severely this representation is affected.
A torn ACL (also known as the anterior cruciate ligament) is one of the most common knee injuries, with as many as 200,000 cases per year in the U.S. Young people under the age of 20 are at particular risk, in part because of participation in sports.
According to a presentation from the American Association of Neurological Surgeons Annual Scientific Meeting, optical topographic imaging is an efficient, novel technique that allows for initial and repeat registration of the cervical spine and had accuracy similar to other spinal neuronavigation systems.
Patients with inflammatory arthritis who underwent total hip arthroplasty experienced higher rates of complications compared with patients who had osteoarthritis, according to results.
The prevalence of obesity in the general population is increasing. Obesity is estimated to affect approximately one-third of adults in the United States. It is estimated that 6.1 million patients who undergo total joint arthroplasty will be obese by 2040.
People with spinal deformity also requiring a total hip replacement are at greater risk for dislocation or follow-up revision surgery, suggesting that these higher-risk patients may benefit from a more personalized approach to their surgeries to reduce the risk of poorer outcomes.
Injury to the anterior cruciate ligament (ACL) in the knee frequently leads to early-onset osteoarthritis, a painful condition that can occur even if the patient has undergone ACL reconstruction to prevent its onset.
A new therapy to treat spinal cord injuries in people who have lost all motor and sensory function below the injury site shows additional motor function improvement at 6-months and 9-months following treatment with 10 million AST-OPC1. The positive efficacy results from an ongoing research study were announced on Jan. 24 in a conference held by Asterias Biotherapeutics, Inc., the biotechnology company that manufactures AST-OPC1.